FDA Announces Advisory Committee Meeting on Sandoz’s Etanercept Biosimilar

Biosimilar News  •  U.S. FDA News

We previously reported on Sandoz’s aBLA for a biosimilar of Amgen’s ENBREL (etanercept) and the related BPCIA litigation.

The FDA’s Arthritis Advisory Committee announced this morning that it will hold a public advisory committee meeting on July 13, 2016 to discuss Sandoz’s etanercept biosimilar. According to the announcement, anyone wishing to make a formal oral presentation must notify the committee contact person by June 20, 2016, and any written submissions must be made by June 28, 2016.

Download PDF

Tagged with 

Comments are closed.